{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:07:12Z","timestamp":1779696432835,"version":"3.53.1"},"reference-count":47,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bimekizumab was well tolerated and demonstrated superior efficacy in global psoriasis studies; however, these included few Chinese patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of bimekizumab in Chinese patients with moderate to severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In BE SHINING, patients were randomized 3:1 to bimekizumab 320\u2009mg every 4\u2009weeks (Q4W) to Week 16 then every 8\u2009weeks (Q8W) to Week 32, or to placebo Q4W to Week 16 then bimekizumab Q4W to Week 32. Primary endpoints included achievement of \u226590% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) and Investigator's Global Assessment (IGA) of 0\/1 at Week 16. Secondary endpoints included PASI 75\/PASI 100 response rates at Week 4\/16, respectively. Missing data were imputed as non\u2010response;\n                      <jats:italic>p<\/jats:italic>\n                      values were based on the Cochran\u2013Mantel\u2013Haenszel test. Safety outcomes were assessed in patients who received \u22651 treatment dose (Weeks 0\u201332).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 133 patients were randomized (bimekizumab Q4W\/Q8W:\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009100; placebo\/bimekizumab Q4W:\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200933). Bimekizumab\u2010treated patients had significantly higher primary endpoint response rates versus placebo (Week 16; PASI 90: 94.0% vs. 3.0%; IGA 0\/1: 92.0% vs. 3.0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 for both), and significantly higher rates of PASI 75 (Week 4; 74.0% vs. 3.0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and PASI 100 (Week 16; 65.0% vs. 0.0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Response rates were similar in bimekizumab Q4W\/Q8W and placebo\/bimekizumab Q4W patients at Week 32. Through Week 32, in patients who received \u22651 bimekizumab dose, rates of treatment\u2010emergent adverse events (TEAEs), serious TEAEs and TEAEs leading to discontinuation were 73.8%, 6.2% and 5.4%. The most common TEAEs were upper respiratory tract infection, hepatic function abnormal and injection site pain; no new safety signals were identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bimekizumab treatment was well tolerated and led to significantly higher clinical response rates versus placebo, including complete skin clearance, in Chinese patients with moderate to severe psoriasis. Findings were consistent with global studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70350","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:23:31Z","timestamp":1770917011000},"page":"1019-1029","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bimekizumab efficacy and safety in Chinese patients with psoriasis in the\n                    <scp>BE SHINING<\/scp>\n                    Phase 3 study"],"prefix":"10.1111","volume":"40","author":[{"given":"Lin","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Dermatology Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-5538","authenticated-orcid":false,"given":"Xiao\u2010Yong","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Affiliated Hospital Zhejiang University School of Medicine  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Ningbo No. 2 Hospital  Ningbo Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Tongren Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"UCB  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Deherder","sequence":"additional","affiliation":[{"name":"UCB  Braine\u2010l'Alleud Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gao","sequence":"additional","affiliation":[{"name":"UCB  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Hoepken","sequence":"additional","affiliation":[{"name":"UCB  Monheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sun","sequence":"additional","affiliation":[{"name":"UCB  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lei","sequence":"additional","affiliation":[{"name":"UCB  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-682X","authenticated-orcid":false,"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the BE SHINING Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle MJ","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley RG","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_13_4_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"8","author":"Damiani G","year":"2021","journal-title":"Front Med"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi R","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s13555-024-01159-3","article-title":"Unmet needs and treatment preference of systemic treatments for moderate\u2010to\u2010severe psoriasis from the perspectives of patients and dermatologists in China","volume":"14","author":"Kuang Y","year":"2024","journal-title":"Dermatol Ther"},{"issue":"2","key":"e_1_2_13_7_1","first-page":"99","article-title":"Biologic treatments for psoriasis in China: current statusand potential tuberculosis and hepatitis B virus risks","volume":"1","author":"Meng Fu WG","year":"2018","journal-title":"Int J Dermatol Venereol"},{"key":"e_1_2_13_8_1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1541292","article-title":"Analysis and contrast of psoriasis disease burden trends in China and globally from 1990 to 2021","volume":"13","author":"Yu K","year":"2025","journal-title":"Front Public Health"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00579","article-title":"Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences","volume":"9","author":"Boehncke WH","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke WH","year":"2011","journal-title":"Exp Dermatol"},{"issue":"2","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5114\/ada.2020.94835","article-title":"The influence of body weight of patients with chronic plaque psoriasis on biological treatment response","volume":"37","author":"Kisielnicka A","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"issue":"1","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biopsych.2014.10.014","article-title":"Meta\u2010analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients","volume":"78","author":"Black C","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"3","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/acps.12458","article-title":"The role of inflammation in suicidal behaviour","volume":"132","author":"Brundin L","year":"2015","journal-title":"Acta Psychiatr Scand"},{"issue":"10","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","article-title":"Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest","volume":"307","author":"Reich K","year":"2015","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita J","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/CCID.S509739","article-title":"Comorbidity pattern in patients with moderate\u2010to\u2010severe plaque psoriasis: network analysis of a hospitalized database in China","volume":"18","author":"Chen W","year":"2025","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"A41","DOI":"10.1016\/j.jval.2014.03.248","article-title":"Prevalence of comorbidites among patients with psoriasis (Pso) with and without psoriatic arthritis (Psa) in European Union (Eu)","volume":"17","author":"Narayanan S","year":"2014","journal-title":"Value Health"},{"issue":"1","key":"e_1_2_13_18_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella ME","year":"2024","journal-title":"J Lipid Res"},{"issue":"1","key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dom.15014","article-title":"Epidemiological characteristics and management of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis in China: a narrative review","volume":"25","author":"Lu R","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"28","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"46381","DOI":"10.18632\/oncotarget.18453","article-title":"Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients","volume":"8","author":"Chen K","year":"2017","journal-title":"Oncotarget"},{"issue":"01","key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JD9.0000000000000074","article-title":"Guidelines for the diagnosis and treatment of psoriasis in China: 2019 concise edition","volume":"03","author":"Zhang X\u2010J","year":"2020","journal-title":"Int J Dermatol Venereol"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2147\/PPA.S357795","article-title":"Patient preference for biologic treatments of psoriasis in the Chinese setting","volume":"16","author":"Lang Y","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL\u201017A and IL\u201017F","volume":"11","author":"Adams R","year":"2020","journal-title":"Front Immunol"},{"issue":"10273","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double\u2010blind, placebo\u2010controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon KB","year":"2021","journal-title":"Lancet"},{"issue":"10273","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52\u2010week, multicentre, double\u2010blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich K","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich K","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren RB","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/bjd\/ljad429","article-title":"Bimekizumab safety in patients with moderate\u2010to\u2010severe plaque psoriasis: pooled data from up to 3\u2009years of treatment in randomized phase III trials","volume":"190","author":"Gordon KB","year":"2024","journal-title":"Br J Dermatol"},{"issue":"6","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3\u2009years in patients with moderate\u2010to\u2010severe plaque psoriasis: results from the BE BRIGHT open\u2010label extension trial","volume":"188","author":"Strober B","year":"2023","journal-title":"Br J Dermatol"},{"issue":"1","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/bjd\/ljaf032","article-title":"Bimekizumab efficacy and safety through 3\u2009years in patients with moderate\u2010to\u2010severe plaque psoriasis: long\u2010term results from the BE RADIANT phase IIIb trial open\u2010label extension period","volume":"193","author":"Warren RB","year":"2025","journal-title":"Br J Dermatol"},{"issue":"1","key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/JID.2015.378","article-title":"Molecular phenotyping small (Asian) versus large (Western) plaque psoriasis shows common activation of IL\u201017 pathway genes but different regulatory gene sets","volume":"136","author":"Kim J","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"3","key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s13555-022-00883-y","article-title":"Bimekizumab efficacy and safety in Japanese patients with plaque psoriasis in BE VIVID: a phase 3, ustekinumab and placebo\u2010controlled study","volume":"13","author":"Asahina A","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/1346-8138.17446","article-title":"Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: a phase 3, randomized, placebo\u2010controlled, double\u2010blinded study","volume":"51","author":"Youn SW","year":"2024","journal-title":"J Dermatol"},{"key":"e_1_2_13_34_1","unstructured":"EMA.Bimekizumab Summary of Product Characteristics.2024.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/bimzelx\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_13_35_1","unstructured":"FDA.Bimekizumab Highlights of Prescribing Information.2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761151s000lbl.pdf"},{"issue":"2","key":"e_1_2_13_36_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00403-015-1613-8","article-title":"Patient\u2010relevant treatment goals in psoriasis","volume":"308","author":"Blome C","year":"2016","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"e_1_2_13_37_1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s13555-019-00334-1","article-title":"Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross\u2010sectional patient survey","volume":"9","author":"Gorelick J","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"e_1_2_13_38_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/09546630903085328","article-title":"Conversations on psoriasis\u2013what patients want and what physicians can provide: a qualitative look at patient and physician expectations","volume":"21","author":"Uhlenhake EE","year":"2010","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"e_1_2_13_39_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate\u2010to\u2010severe plaque psoriasis: results from a phase 3, randomized, placebo\u2010controlled, double\u2010blind study","volume":"31","author":"Cai L","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"22","key":"e_1_2_13_40_1","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52\u2009weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai L","year":"2020","journal-title":"Chin Med J"},{"issue":"1","key":"e_1_2_13_41_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1684\/ejd.2024.4599","article-title":"Effectiveness of guselkumab in patients with moderate\u2010to\u2010severe plaque psoriasis: a retrospective study from China","volume":"34","author":"Huang H","year":"2024","journal-title":"Eur J Dermatol"},{"issue":"12","key":"e_1_2_13_42_1","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1007\/s12325-023-02672-1","article-title":"Safety and efficacy of ixekizumab in Chinese adults with moderate\u2010to\u2010severe plaque psoriasis: a prospective, multicenter, observational study","volume":"40","author":"Ying L","year":"2023","journal-title":"Adv Ther"},{"issue":"4","key":"e_1_2_13_43_1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/ced\/llae400","article-title":"The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16\u2010week multicentre real\u2010world experience \u2013 IL PSO (Italian landscape psoriasis)","volume":"50","author":"Megna M","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"e_1_2_13_44_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41522-022-00343-7","article-title":"The salivary microbiome shows a high prevalence of core bacterial members yet variability across human populations","volume":"8","author":"Ruan X","year":"2022","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"2","key":"e_1_2_13_45_1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1086\/345672","article-title":"Geographical differences in human oral yeast flora","volume":"36","author":"Xu J","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"11","key":"e_1_2_13_46_1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jpain.2010.02.015","article-title":"Comparisons of catastrophizing, pain attitudes, and cold\u2010pressor pain experience between Chinese and European Canadian young adults","volume":"11","author":"Hsieh AY","year":"2010","journal-title":"J Pain"},{"key":"e_1_2_13_47_1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1127489","article-title":"Prevalence of nonalcoholic fatty liver disease and the related risk factors among healthy adults: a cross\u2010sectional study in Chongqing, China","volume":"11","author":"Kong L","year":"2023","journal-title":"Front Public Health"},{"issue":"4","key":"e_1_2_13_48_1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta\u2010analysis","volume":"70","author":"Zhou F","year":"2019","journal-title":"Hepatology"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70350","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:51:04Z","timestamp":1779695464000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/jdv.70350"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70350","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"2025-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}